Biomarker Testing and Treatment inEarly-Stage Non-Small Cell Lung Cancer

Latest research findings as well as ongoing clinical trials on the use of chemotherapy, targeted therapy, and immunotherapy in early-stage NSCLC

Key Takeaways

  • Have been diagnosed with stage IA, IB or IIA non-squamous non-small cell lung cancer (NSCLC) with a tumor size of less than 5 cm and with no nodal involvement (N0)
  • Current standard of care in NSCLC has poor outcomes when compared to other early-stage cancers.
  • DetermaRx is changing how we manage
    NSCLC by driving molecular testing to earlier stages of cancer when we have the best chance to impact patient outcomes.

EGFR and Molecular Risk Stratification inEarly-Stage Non-Small Cell Lung Cancer

New prospective data about EGFR and molecular risk stratification in early-stage NSCLC, followed by an engaging panel discussion with lung cancer experts.

Key Takeaways

  • Combining DetermaRxTM risk status with EGFR mutation status may help inform optimal treatment strategies for non-small cell lung cancer (NSCLC) patients who are EGFR-mutation-positive.
  • DetermaRxTM may inform the usage of chemotherapy, in addition to osimertinib, in the approximately 33% of EGFR positive patients who DetermaRx identified as high-risk for cancer recurrence.